Axiom Catalyst

Best Foot Forward: Optimizing Clinical Trials during Today's Crossroads – Moderated by Giovanni Abbadessa of ModeX, this insightful panel features Lisa Mahnke of Nerviano Medical Sciences and Christiana Bardon of MPM. Discover how these leaders are optimizing clinical trials and evaluating asset strength in today's rapidly evolving healthcare landscape.

To learn more about how we can help you develop your pre-clinical platform and prioritize effective clinical development plans, reach out to our Chief of Strategy, Anne Cherry, at [email protected]

Watch the full discussion here: https://www.youtube.com/watch?v=pKMls_9UV80

#ClinicalTrials #HealthcareInnovation #AxiomSummit #MedicalResearch

Crossroads Between Oncology & Rare Diseases – Moderated by Anne Cherry, this panel features Michelle Werner from Alltrna. Explore the critical intersections of oncology and rare diseases, and how insights from one world can provide insight to the other.

Watch the full panel here: https://www.youtube.com/watch?v=1e6Ozg2_YL0

To learn more about our work supporting companies driving innovation across oncology and rare disease, reach out to Anne at [email protected]

#Oncology #RareDiseases #HealthcareInnovation #AxiomSummit

Reimagining Clinical Trials – A thought-provoking panel moderated by the Managing Principal of Axiom Healthcare Strategies, featuring exertise among physicians and industry leaders: Hossein Borghaei, Corey Langer, Shruti Agrawal, Robert LaCaze, Alan Bash, and Nicholas Davies. Explore innovative approaches transforming traditional trial models.

To learn more about our work supporting innovation in study designs, reach out to our Chief of Strategy, Anne Cherry, at [email protected]

Watch the full panel here: https://youtu.be/Jf_4J9YZLI4?feature=shared

#ClinicalTrials #FutureOfClinicalTrials #InnovatingResearch #ClinicalTrialsReimagined #AxiomSummit

CEO and Founder Spotlight – A dynamic panel moderated by the Managing Principal of Axiom Healthcare Strategies, featuring industry leaders, Alan Bash, Lea Hachigian, Robert LaCaze, and Michelle Werner. Dive into their journeys, insights, and visions for the future of healthcare.

To learn more about how Axiom supports biotech leaders and their organizations to excel, reach out to our Chief of Strategy, Anne Cherry, at [email protected]

Watch the full panel discussion here: https://www.youtube.com/watch?v=sdfYENHWR28

#Leadership #HealthcareInnovation #AxiomSummit #Entrepreneurship

Anne Cherry, Chief of Strategy at Axiom Healthcare Strategies, dives deep into identifying gaps and opportunities across the product development lifecycle. Learn how strategic insights are transforming patient outcomes and driving innovation.

Partnering for Innovation – A powerful discussion led by Paul Biondi of Flagship Pioneering at the Axiom Crossroads Summit! Explore insights on how groundbreaking collaborations are shaping the future of healthcare and driving innovation.

From the first new treatment in locally advanced cervical cancer in over a decade to buzz around exciting new drugs in development for ovarian and endometrial cancer, there have been many advances made in gynecologic cancer treatment in the past 12 months. 

In this Gynecologic Cancer Awareness Month special episode of Axiom Catalyst, Carlie Darefsky, Harish Venkatesan, Flannery Nania, and Luke Anderson talk through the challenges and hope for patients of gynecologic cancers. 

This podcast complements the infographics the Axiom team developed to highlight specific needs and challenges in cervical, ovarian, and endometrial cancers.

#GynecologicCancer #GynAwarenessMonth2024 #AxiomThinkTank

Over the past few decades, bladder cancer standard of care has not changed, with platinum-based chemotherapy and BCG as the core pillars of care. The last 12 months have seen two new regimens approved for frontline locally advanced / metastatic urothelial and one new treatment approved for BCG-unresponsive CIS NMIBC, significantly improving survival outcomes for patients. Many other clinical programs have continued progressing, ushering in a new wave of novel, targeted, and potentially more tolerable bladder cancer treatments. 

In this Bladder Cancer Awareness Month special episode of Axiom Catalyst, Andrew Kassin and Kiana Ziadkhanpour interview Dr. Petros Grivas, a thought-leading GU Medical Oncologist of University of Washington and Fred Hutchinson Cancer Center, to discuss innovative bladder cancer treatments, changing treatment practices, and patient risk factors. 

We are honored to continue spreading awareness for bladder cancer to help patients around the world! #BladderCancerAwarenessMonth2024 #AxiomThinkTank

Severe care disparities, barriers to diagnosis, harrowing patient stories, historically low survival… and yet… enduring hope for women worldwide.
While significant progress has been made to address needs of women with gynecologic cancers, and the last 12 month have seen huge strides in advancing standards of care, key challenges remain including the inclusivity of clinical studies, asymmetric engagement and awareness across communities, and limited ability to tailor therapies, especially in later lines as care options dry up.
In this this Gynecologic Cancer Awareness Month special episode of Axiom Catalyst, Dan Simpson, Carlie Darefsky, Harish Venkatesan and Flannery Nania talk through the challenges and hope for patients, as we look to the healthcare industry to raise the bar on health standards.
This short podcast complements the specific infographics the Axiom team developed to highlight specific needs and challenges in cervical, ovarian and endometrial cancers respectively.

Let’s keep raising awareness and saving lives! 🌸💪

#CervicalCancer #OverianCancer #EndometrialCancer #HealthcareAdvocacy #TogetherAgainstCancer #GynecologicCancer #GynAwarenessMonth2023 #AxiomThinkTank 

Dr. Han Phan is a member of the Pediatric Advisory Board at the FDA, and the Director of Rare Disease Research center. She joins the Axiom Table with Akash Bhattacharjee. This discussion goes though her experience with diagnosing and treating Duchenne patients, challenges faced by manufacturers in this space, and one of the most eagerly anticipated news of the year in Pharma.